🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluating Residual Congestion at Discharge in Acute Heart Failure Patients

Recruitingn/aAges 18 Years - anyAllConsorci Sanitari Integral
NCT06993220 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Treatment of congestion is one of the main goals in patients hospitalized for acute heart failure. Nevertheless, current evidence shows that decongestion is often not achieved and that residual congestion at discharge is strongly associated with poor outcomes. While this association has been demonstrated, previous studies have primarily focused on single parameters of congestion (physical examination, biomarkers, or imaging features). The aim of the study is to assess residual congestion at discharge using a multiparametric approach and to compare the prognostic value of each evaluation strategy. Additionally, the analysis will be supported by artificial intelligence to develop a multiparametric prognostic algorithm that can provide an improved predictive model compared to standard statistical approaches.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years. * Patients hospitalized for new onset heart failure or worsening heart failure defined by: 1. Symptoms classified as New York Heart Association class III or IV. 2. Clinical or instrumental signs of volume overload (e.g., dyspnea with evidence of pulmonary congestion on X-rays or lung ultrasound, pitting edema, and jugular venous distension). 3. Elevated NT-proBNP levels within the first 24 hours of admission (cutoff values: 450 ng/L for patients \< 50 years; \>900 ng/L for patients aged 50-75 years; \>1800 ng/L for patients \>75 years). * Ability to provide informed consent. Exclusion Criteria: * Known diagnosis of septicemia. * Glomerular filtration rate \< 15 ml/min. * Life expectancy \< 6 months. * Active myocarditis. * Heart transplant recipients. * Patients with ventricular assist devices. * Congenital heart diseases. * Moderate-to-severe liver disease (Child-Pugh B-C). * Patients that will not be followed up by the Heart Failure Unit.
💊

What it tests

  • Evaluation of residual congestion at discharge
📍

Where

1 site
Complex Hospitalari Universitari Moisès Broggi
Sant Joan Despí, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy